

Biographical sketch CIRO ISIDORO



Name CIRO ISIDORO

Email ciro.isidoro@med.uniupo.it

Qualified Full Professor of Clinical Biochemistry and Clinical Molecular Biology

Qualified Full Professor of Medical Oncology

Qualified Full Professor of General Pathology and Clinical Pathology

Appointed Associate Professor of General Pathology

Affiliation Università del Piemonte Orientale, Department of Health Sciences; via Paolo Solaroli 17 – 28100, Novara (Italy)

Website: <http://www.isidorolab.com/>

Education:

1983 – Laurea *Summa cum Laude* - Doctor in Biological Sciences (D.Sc.), Università di Torino (Italy)

1984 – National License for Board of Doctor Biologists

1999 - Laurea *Summa cum Laude* - Doctor in Medicine and Surgery (M.D.), Università del Piemonte Orientale (Novara, Italy)

2000 – National License for Board of Medical Doctors and Surgeons.

Representative Careers and affiliations:

1986-1989: PhD fellow-Assistant Researcher at the Institut fuer Pathobiochemie, Westfaelish Wilhems Universitaet Muenster (Germany)

1989-1992: Post-doc-Assistant Researcher at Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Italy)

1993-1999: Assistant Professor of General Pathology, University of Turin (Italy)

2000 to date: Associate Professor of Cell Pathology and of Experimental Oncology, School of Medicine, Università del Piemonte Orientale (Novara, Italy).

2000-2000: Visiting Professor at Institute fuer Physiologische Chemie (Prof. A. Hasilik), Klinikum der Philipps-Universitaet Marburg (D)

2002-2005: Visiting Professor at Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol (UK).

2005 to date: overseas advisor of PhD students at Mahidol University, at Chulalongkorn University, Bangkok; at Khon Kaen University (Thailand)

2013 to 2018: Visiting Professor, Siriraj Faculty of Medicine, Mahidol University of Bangkok (Thailand).

2016 to date: Visiting Professor, Department of Cell Biology, Oklahoma University Health Science Center (OKC, US).

2018 to date: Visiting Professor, Faculty of Allied Health Sciences, Chulalongkorn University of Bangkok (Thailand).

Representative Awards:

2014: Professor Honoris Causa Faculty of Medicine and Pharmacy, Université de la Franche-Comté of Besançon (Fr)

Biographical sketch CIRO ISIDORO

ance).

2015: member of the Scientific board of « Integrative Cancer Research Center of the Georgia Institute of Technology », Georgia Tech University, Georgia (Atlanta, US)

2015: Executive Vice-President of the International Association of Traditional and Complementary Medicine.

EDITORIAL BOARD *Co-Editor-in-Chief* of J Traditional and Complementary Medicine; *Associate Editor of* Autophagy, Molecular Carcinogenesis, BMC Cancer, Int J Molec Sci, Genes and Cancer, J. Ovarian Research, J. Molecular Signaling, Frontiers in Endocrinology and Ageing, Am J Cancer Biol, (others)

Bibliometric index: Google Scholar H Index = 36; Citations >11400; Scopus H Index = 33

Publication list PUBMED <https://www.ncbi.nlm.nih.gov/pubmed/?term=isidoro+c>

Research Areas: Autophagy in Cancer and in Neurodegeneration. Epigenetic regulation of Autophagy and cell death. Anti-aging and anti-cancer Nutraceuticals. Organelle biogenesis, vesicular traffic and diseases. Nanotheranostics ('in cellulo' imaging).

Selected Publications:

1: Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. *Cancer Lett.* 2019 Feb 1;442:464-474. doi:10.1016/j.canlet.2018.11.023.

2: Thongchot S, Ferraresi A, Vidoni C, Loilome W, Yongvanit P, Namwat N, Isidoro C. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. *Cancer Lett.* 2018 Aug 28;430:160-171. doi: 10.1016/j.canlet.2018.05.031.

3: Thongchot S, Vidoni C, Ferraresi A, Loilome W, Yongvanit P, Namwat N, Isidoro C. Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway. *Mol Carcinog.* 2018 Dec;57(12):1735-1750. doi: 10.1002/mc.22893.

4. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley KM, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. *Cancer Res.* 2018 Jan 31. pii: canres.1624.2017. doi:10.1158/0008-5472.CAN-17-1624.

5. Thuwajit C, Ferraresi A, Titone R, Thuwajit P, Isidoro C. The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role. *Med Res Rev.* 2017 Sep 19. doi:10.1002/med.21473.

6: Ferraresi A, Titone R, Follo C, Castiglioni A, Chiorino G, Dhanasekaran DN, Isidoro C. The protein restriction mimetic Resveratrol is an autophagy inducer stronger than amino acid starvation in ovarian cancer cells. *Mol Carcinog.* 2017 Dec;56(12):2681-2691. doi: 10.1002/mc.22711. Epub 2017 Sep 7.

7: Phadngam S, Castiglioni A, Ferraresi A, Morani F, Follo C, Isidoro C. PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. *Oncotarget.* 2016 Dec 20;7(51):84999-85020. doi: 10.18632/oncotarget.13113.

8: Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, Chiorino G, Isidoro C. Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. *Mol Carcinog.* 2017 Mar;56(3):1164-1181. doi: 10.1002/mc.22582.

9. Klionsky DJ, et al., Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy.* 2016 Jan 2;12(1):1-222.

Biographical sketch CIRO ISIDORO

10: Janda E, Lascalea A, Carresi C, Parafati M, Aprigliano S, Russo V, Savoia C, Ziviani E, Musolino V, Morani F, Isidoro C, Mollace V. Parkinsonian toxin-induced oxidative stress inhibits basal autophagy in astrocytes via NQO2/quinoneoxidoreductase 2: Implications for neuroprotection. *Autophagy*. 2015 Jul;11(7):1063-80. doi: 10.1080/15548627.2015.1058683.

11: Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, Hibshoosh H, Xiao G, Packer M, Xie Y, Levine B. Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. *EBioMedicine*. 2015 Mar;2(3):255-263.